Back to search

Article

A Systems Biology and Generative Artificial Intelligence Framework for Rational Multi-Target Drug Design in Metabolic Dysfunction-Associated Steatotic Liver Disease: Proof-of-Concept Identification of HPM-001

2026-08-10

Abstract excerpt

<title>Abstract</title> <p> <bold>Introduction:</bold> Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide and is characterized by complex interactions among metabolic, inflammatory, and fibrogenic pathways. Current pharmacological strategies predominantly target single molecular mechanisms, limiting their ability to address the multifactorial...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3b5b40f4-d061-5f8a-9b6f-9269fcd1013a
DOI
10.21203/rs.3.rs-10620781/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Systems Biology and Generative Artificial Intelligence Framework for Rational Multi-Target Drug Design in Metabolic Dysfunction-Associated Steatotic Liver Disease: Proof-of-Concept Identification of HPM-001DOI 10.21203/rs.3.rs-10620781/v1
Network Pharmacology Integrated with Multi-Dataset Machine Learning Identifies Core Diagnostic Biomarkers and Elucidates the Molecular Mechanism of a Traditional Chinese Medicine Transdermal Formula Against Non-Alcoholic Fatty Liver DiseaseSemantic proximity
Mechanistic systems modeling to guide drug discovery and development.Semantic proximity
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biologySemantic proximity
Integrating text mining with network models for successful target identification: in vitro validation in MASH-induced liver fibrosisSemantic proximity
Combined stem cell and predictive models reveal flavin cofactors as targets in metabolic liver dysfunctionSemantic proximity
Mechanisms of Yinchen combined with Huangbai against Non-alcoholic fatty liver disease based on Network pharmacology, Molecular docking and Molecular Dynamics SimulationsSemantic proximity
Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver DiseaseSemantic proximity
A panorama to mine “bioactive X” against progressive deterioration of liver disease: from NAFLD to HCCSemantic proximity
Computational Identification of Natural Product-Derived GSK-3β Inhibitors as Candidate Therapeutics for Type 2 Diabetes and MASHSemantic proximity
Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASHSemantic proximity
Integrating Network Pharmacology and Experimental Validation to Elucidate Huaier in Attenuating Liver Fibrosis via the AKT Signaling PathwaySemantic proximity
Repositioning of a Novel GABA-B Receptor Agonist, AZD3355&nbsp;(Lesogaberan), for the Treatment of Non-alcoholic SteatohepatitisSemantic proximity
Select a neighboring publication to make it the new centre.